Literature DB >> 20303455

Updated principles and clinical caveats in the management of infection in renal transplant recipients.

Ravi Parasuraman1, Dilip Samarapungavan, K K Venkat.   

Abstract

Renal transplantation is now considered the treatment of choice for patients with end-stage renal disease. In transplant recipients, infection and rejection are entwined and are unavoidable tribulations unless clinical tolerance becomes a reality. Although rejection rates have significantly decreased with the introduction of newer immunosuppressive agents, infections remain a major cause of morbidity and mortality, and the magnitude of the problem is on the rise. Newer infections are emerging and patterns of known infections are changing. The continuous evolution of donor and recipient characteristics also alters the landscape of infections. In clinical practice, establishing a definite diagnosis of infection in a timely manner remains a challenge in transplant recipients as compared to immunocompetent individuals. Hence a comprehensive knowledge of the principles of management of infections in renal transplant recipients is very essential. In this review, we would like to provide an overview of some of the key principles that we believe are essential in the management of infectious complications in renal transplant recipients with no focus on any individual infection. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20303455     DOI: 10.1016/j.trre.2009.09.001

Source DB:  PubMed          Journal:  Transplant Rev (Orlando)        ISSN: 0955-470X            Impact factor:   3.943


  4 in total

1.  Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.

Authors:  Justine Bacchetta; Jessica L Sea; Rene F Chun; Thomas S Lisse; Katherine Wesseling-Perry; Barbara Gales; John S Adams; Isidro B Salusky; Martin Hewison
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

Review 2.  Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?

Authors:  Justine Bacchetta; Isidro B Salusky; Martin Hewison
Journal:  Pediatr Nephrol       Date:  2012-11-02       Impact factor: 3.714

3.  Fibroblast growth factor 23 weakens chemotaxis of human blood neutrophils in microfluidic devices.

Authors:  Ke Yang; Hagit Peretz-Soroka; Jiandong Wu; Ling Zhu; Xueling Cui; Michael Zhang; Claudio Rigatto; Yong Liu; Francis Lin
Journal:  Sci Rep       Date:  2017-06-08       Impact factor: 4.379

4.  Epstein-Barr virus and cytomegalovirus infections and their clinical relevance in Egyptian leukemic pediatric patients.

Authors:  Samah Aly Loutfy; Maha A Abo-Shadi; Mohamed Fawzy; Mohamed El-Wakil; Shimaa A Metwally; Manar M Moneer; Nasra F Abdel Fattah; Sara Kassem; Ahmed Elgebaly
Journal:  Virol J       Date:  2017-03-06       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.